Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. Charing Cross Hospital, Imperial College London, London, United Kingdom

Survival: 25.0 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: United Kingdom
City/State/Province: London
Hospital: Charing Cross Hospital, Imperial College London
Journal: Link
Date: 7/2009

Patients: This phase 2 study involved 51 women with metastatic breast cancer. Their median age was 55, ranging from 35 to 69.

Treatment: These patients were treated with the chemotherapy drugs docetaxel and doxorubicin. The doxorubicin they were given was in a form called ‘non-pegylated liposomal’.

Toxicity: The most common grade 3 and 4 toxicities were leucopenia and neutropenia, which were reported in 80 and 74% of patients, respectively. Other grade 3 and 4 toxicities were infection, fatigue, diarrhea, and nausea.

Results: The median overall survival was 25 months.

Support: This research study was supported by Cephalon Pharma, Aventis Pharmaceutical, and Amgen Pharmaceutical. Cephalon markets non-pegylated liposomal doxorubicin as Myocet, and Aventis markets docetaxel as Taxotere.

Correspondence: Dr. Peter Schmid

E-mail to a Friend Email Physician More Information